Clinical Trial

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate the efficacy and safety of GZR18 Injection in this population.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-27.
Status change: Not Yet Recruiting → Recruiting 2025-11-20
Trial Details
NCT Number NCT07150975
Lead Sponsor Gan & Lee Pharmaceuticals.
Conditions Obesity/Overweight in Adult
Enrollment 420 participants
Start Date 2025-09-23
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-25